- Rha, S., Kawazoe, A., Bai, Y., Xu, J., Lonardi, S., Metges, J.,…Tabernero, J., …Janjigian, Y. (2024). Final overall survival for the phase III, KEYNOTE-811 study of pembrolizumab plus trastuzumab and chemotherapy for HER2+advanced, unresectable or metastatic G/GEJ adenocarcinoma. Annals of Oncology, 35, S1453-1454. https://doi.org/10.1016/j.annonc.2024.10.154 (Meeting abstract)
Final overall survival for the phase III, KEYNOTE-811 study of pembrolizumab plus trastuzumab and chemotherapy for HER2+advanced, unresectable or metastatic G/GEJ adenocarcinoma
on 12 de maig de 2025
with No hi ha comentaris
Deixa un comentari